SNP-ACTH Gel not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Membranous Nephropathy
- Main trialPhase 3
- “The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.”In the company’s words, NCT05696613 on ClinicalTrials.gov
Other drugs for Primary Membranous Nephropathy
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- BelzutifanMerck & Co. · Phase 3
- AbexinostatXynomic Pharmaceuticals, Inc. · Phase 3
Coming up1
- 1 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Apr 2027 | A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026